title: Evaluation of Tigecycline Efficacy and Post-Discharge Outcomes in a Clinical Practice Population with Complicated Intra-Abdominal Infection: A Propensity Score-Matched Analysis.
abstract: BACKGROUND
  The utility of tigecycline as compared with other antibiotic therapies in the treatment of patients with complicated intra-abdominal infection (cIAI) and the short- and long-term outcomes of a large cohort of severely ill patients were examined. We provide the first published data on post-discharge events for these patients.
  
  
  METHODS
  Retrospective data for the cIAI cohort were obtained from a large clinical database. Patients aged ≥18 y were selected for inclusion based on hospitalization with a relevant diagnosis code and procedure code, and guideline-compliant antimicrobial therapy. Propensity scoring was used to reduce treatment-selection bias introduced by the use of observational data. Tigecycline patients were placed into quintiles based on propensity score and were matched 1:3.
  
  
  RESULTS
  The final model based on propensity score matching included 2,424 patients: Tigecycline (n = 606) and other antibiotic therapy (n = 1,818). Treatment was successful in 426 (70.3%) tigecycline-treated patients and in 1,294 (71.2%) patients receiving other antibiotics. Similar treatment success occurred across all infection sites. Among survivors, treatment failure was associated with a greater need for all-cause re-hospitalization at 30 d and 180 d. No differences in cIAI-related re-hospitalization and discharge status were observed.
  
  
  CONCLUSIONS
  Using propensity scores to match populations, similar outcomes were demonstrated between treatment with tigecycline and other antibiotics as expressed by treatment success, the need for re-admission, similar 30-d discharge status, and the need for re-admission at 180 d.
authors.affiliation: 1 University of Cincinnati College of Medicine , Cincinnati, Ohio.
authors.forename: Joseph
authors.initials: J
authors.lastname: Solomkin
authors.affiliation: 2 Pharmaceutical Health Services Research, University of Maryland School of Pharmacy , Baltimore, Maryland.
authors.forename: C Daniel
authors.initials: CD
authors.lastname: Mullins
authors.affiliation: 3 Medicine Development Group , Pfizer Inc, Collegeville, Pennsylvania.
authors.forename: Alvaro
authors.initials: A
authors.lastname: Quintana
authors.affiliation: 4 Klinkum Peine Academic Hospital of Medical University Hannover , Peine, Germany .
authors.forename: Christian
authors.initials: C
authors.lastname: Eckmann
authors.affiliation: 3 Medicine Development Group , Pfizer Inc, Collegeville, Pennsylvania.|5 Columbia School of Public Health , New York, New York.
authors.forename: Ahmed
authors.initials: A
authors.lastname: Shelbaya
authors.affiliation: 6 Indegene TTM , Kennesaw, Georgia .
authors.forename: Frank R
authors.initials: FR
authors.lastname: Ernst
authors.affiliation: 7 Quintiles , Cambridge, Massachussetts.
authors.forename: Michelle R
authors.initials: MR
authors.lastname: Krukas
authors.affiliation: 8 Global Innovative Pharma Business , Pfizer Inc, New York, New York.
authors.forename: Arlene
authors.initials: A
authors.lastname: Reisman
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D059413:Intraabdominal Infections / Q000188:drug therapy*; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D008911:Minocycline / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010359:Patient Readmission / Q000706:statistics & numerical data; D057216:Propensity Score; D012008:Recurrence; D000078304:Tigecycline; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000078304:Tigecycline; D008911:Minocycline